Eupraxia Pharmaceuticals Inc.
EPRX Nasdaq
SEC CIK 1581178
Follow Eupraxia Pharmaceuticals
Weekly email: filings, results
Revenue, last year
$0
Net income
−$38.6M
−51.3% vs prior year
EPS, diluted
−$1.03
−35.5% vs prior year
Operating cash flow
−$28.6M
+4.8% vs prior year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$38.6M |
| FY24 | $0 | −$25.5M |
| FY23 | $0 | −$28.2M |
| FY22 | - | −$18.5M |
| FY21 | - | - |